Effects of practolol on pressor responses to noxious stimuli in hypertensive patients

The effect of practolol, a ß‐adrenergic blocker, on the cardiovascular response to noxious stimuli was studied in 10 patients with mild to moderate hypertension. Two oral dose levels of 400 and 800 mg. per day were employed in a short‐term study that was carefully monitored by blood levels of the drug; the effects were compared to that of an identical placebo administered in a double blind fashion. Results indicated no change in the resting blood pressure or pulse rate in these patients at either dose level. Similarly, the pressor responses to ischemic pain and cold pressor testing were not affected. However, responses of the pulse rate to the stimuli and to 60 degree tilt were Significantly dampened. Hemodynamic studies were done in 3 patients and revealed no consistent patterns of change in the relationships between cardiac output and peripheral resistance during the pressor responses. No adverse symptomatic or systemic side effects were noted at either dose level. The results confirmed the relative ineffectiveness of this compound as a sole agent in treating hypertensive patients but suggest it may be of some value as a supplement to vasodilator compounds.

[1]  P. Lockwood,et al.  [Use of propranolol in treatment of hypertension]. , 1972, Revue medicale de Liege.

[2]  H. Hochberg,et al.  Accuracy of an automated ultrasound blood pressure monitor. , 1971, Current therapeutic research, clinical and experimental.

[3]  J. Thirkettle,et al.  Controlled Trial of Oxprenolol and Practolol in Hypertension , 1970, British medical journal.

[4]  B. Prichard,et al.  The effect of graded doses of practolol on the tachycardia induced by isoprenaline, Valsalva's manoeuvre and exercise. , 1970, British journal of pharmacology.

[5]  J. Fitzgerald Perspectives in adrenergic beta‐receptor blockade , 1969, Clinical pharmacology and therapeutics.

[6]  S. Moutsos,et al.  Effects of propranolol on the pressor response to noxious stimuli in hypertensive patients. , 1968, The American journal of cardiology.

[7]  R G Shanks,et al.  Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise , 1968, British journal of pharmacology.

[8]  E. Frohlich,et al.  Immediate Hemodynamic Effects of Beta‐Adrenergic Blockade with Propranolol in Normotensive and Hypertensive Man , 1968, Circulation.

[9]  E. Frohlich,et al.  The Paradox of Beta‐Adrenergic Blockade in Hypertension , 1968, Circulation.

[10]  S. Moutsos,et al.  An analysis of the placebo effect in hospitalized hypertensive patients , 1967, Clinical pharmacology and therapeutics.

[11]  C. Dollery,et al.  Effect of propranolol in mild hypertension. , 1966, Lancet.

[12]  K. Hutchison,et al.  Effects of propranolol on peripheral vessels in man. , 1966, The American journal of cardiology.

[13]  H. Waal Hypotensive action of propranolol , 1966, Clinical pharmacology and therapeutics.

[14]  A. P. Shapiro,et al.  Studies in Man on the Relationship of Adrenergic Correlates to Pressor Responsivity , 1966, Circulation.

[15]  S. Moutsos,et al.  Comparative studies of methyldopa and placebo in hospitalized hypertensive patients. , 1965, The American journal of cardiology.

[16]  A. P. Shapiro,et al.  Pressor Responses to Noxious Stimuli in Hypertensive Patients: Effects of Guanethidine Sulfate and Alpha Methyldopa , 1964, Circulation.

[17]  A. P. Shapiro,et al.  An experimental study of comparative responses of blood pressure to different noxious stimuli , 1961 .

[18]  R. Ahlquist,et al.  A study of the adrenotropic receptors. , 1948, The American journal of physiology.

[19]  R G Shanks,et al.  Selective blockade of adrenoceptive beta receptors in the heart. , 1968, British journal of pharmacology and chemotherapy.

[20]  J. Fitzgerald,et al.  Effect of a new adrenergic beta-blocking agent (ICI 50,172) on heart rate in relation to its blood levels. , 1968, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology.